An observational study in Relapsing Remitting Multiple Sclerosis (RRMS) and Malnutrition or Risk of Malnutrition, sponsored by Antalya Training and Research Hospital. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Antalya Training and Research Hospital · Observational
This prospective observational study aims to determine the prevalence of malnutrition in patients with relapsing-remitting multiple sclerosis and to evaluate its association with disability. Nutritional status will be assessed using the Mini Nutritional Assessment-Short Form, and body composition will be evaluated with bioelectrical impedance analysis and anthropometric measurements. The study will also assess urinary incontinence, depression, and anger-related features, and compare the findings with those of healthy controls.
Multiple sclerosis is a chronic inflammatory and demyelinating disease of the central nervous system that may lead to disability, reduced mobility, bladder dysfunction, depression, and impaired quality of life. In the early stages of the disease, overweight and obesity may be common, whereas with disease progression, malnutrition and cachexia may become more prominent. Malnutrition may contribute to muscle loss, reduced mobility, worsening functional status, and increased clinical burden.
This single-center, hospital-based, prospective cross-sectional observational study will be conducted in the multiple sclerosis and neurology outpatient clinics of Antalya Training and Research Hospital. Adult patients diagnosed with relapsing-remitting multiple sclerosis and healthy controls will be included. Nutritional status will be assessed using the Mini Nutritional Assessment-Short Form. Body composition and anthropometric parameters, including waist-to-height ratio, waist-to-hip ratio, body fat percentage, fat mass, fat-free mass, total body water, and predicted muscle mass, will be evaluated using bioelectrical impedance analysis and standard anthropometric measurements. Disability in the patient group will be assessed with the Expanded Disability Status Scale. Depression, anger-related characteristics, and urinary incontinence profiles will also be evaluated using structured questionnaires and validated scales.
The study is designed to investigate the prevalence of malnutrition in relapsing-remitting multiple sclerosis, compare nutritional and related clinical parameters with healthy controls, and examine the relationship between malnutrition, body composition, and disability.
602 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 80 are open to participants now.
This study's enrollment of 169 is above the median of 116 across 151 observational studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Browse Multiple Sclerosis, Relapsing-Remitting studies →Antalya Training and Research Hospital is the lead sponsor of 102 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study population will consist of adults aged 18 years or older. The patient group will include individuals with relapsing-remitting multiple sclerosis who are followed in the neurology outpatient clinic of Antalya Training and Research Hospital and meet the predefined inclusion and exclusion criteria. A healthy control group of adult volunteers without multiple sclerosis will be recruited for comparison.
Exclusion Criteria:
Patients with Relapsing-Remitting Multiple Sclerosis
Healthy Controls
Prevalence of malnutrition assessed by Mini Nutritional Assessment-Short Form
Malnutrition status and risk of malnutrition will be assessed using the Mini Nutritional Assessment-Short Form (MNA-SF) in patients with relapsing-remitting multiple sclerosis and healthy controls. MNA-SF is a screening tool with a total score ranging from 0 to 14. Lower scores indicate worse nutritional status. Scores from 12 to 14 indicate normal nutritional status, scores from 8 to 11 indicate risk of malnutrition, and scores from 0 to 7 indicate malnutrition. The relationships between MNA-SF and anthropometric, body composition, depressive and anger-related variables will also be evaluated.
Time frame: At baseline
Expanded Disability Status Scale score
Disability severity will be assessed in patients with Multiple Sclerosis (MS) using the Expanded Disability Status Scale (EDSS), which ranges from 0 to 10 in 0.5-point increments. Higher scores indicate worse disability. A score of 0 indicates normal neurological status, and a score of 10 indicates death due to MS. The relationships between disability severity and anthropometric, body composition, depressive, anger-related, and urinary incontinence-related variables will also be evaluated.
Time frame: At baseline
Height as an anthropometric measurement
Height will be measured in meters in both patients with relapsing-remitting multiple sclerosis and healthy controls.
Time frame: At baseline
Body weight as an anthropometric measurement
Body weight will be measured in kilograms in both patients with relapsing-remitting multiple sclerosis and healthy controls.
Time frame: At baseline
Body mass index as an anthropometric measurement
Body mass index (BMI) will be calculated in kilograms per square meter (kg/m²) using measured body weight and height in both patients with relapsing-remitting multiple sclerosis and healthy controls.
Time frame: At baseline
Waist circumference as an anthropometric measurement
Waist circumference will be measured in centimeters in both patients with relapsing-remitting multiple sclerosis and healthy controls.
Time frame: At baseline
Hip circumference as an anthropometric measurement
Hip circumference will be measured in centimeters in both patients with relapsing-remitting multiple sclerosis and healthy controls.
Time frame: At baseline
Waist-to-height ratio as an anthropometric measurement
Waist-to-height ratio (WHtR) will be calculated using waist circumference and height measurements in both patients with relapsing-remitting multiple sclerosis and healthy controls. Higher values indicate greater central adiposity.
Time frame: At baseline
Waist-to-hip ratio as an anthropometric measurement
Waist-to-hip ratio (WHR) will be calculated using waist circumference and hip circumference measurements in both patients with relapsing-remitting multiple sclerosis and healthy controls.
Time frame: At baseline
Fat mass (kg)
Fat mass (FM) will be measured in kilograms using the TANITA® MC-180MA Bioelectric Impedance Analyser device in both patients with RRMS and healthy controls. Bioelectrical impedance analysis will be performed 2 hours after a meal, following 5 minutes of rest, with participants standing still on the device with bare hands and feet.
Time frame: At baseline
Fat mass (%)
Fat mass percentage will be derived from fat mass relative to body weight and expressed as a percentage in both patients with RRMS and healthy controls. Measurements will be obtained using the TANITA® MC-180MA Bioelectric Impedance Analyser. Bioelectrical impedance analysis will be performed 2 hours after a meal, following 5 minutes of rest, with participants standing still on the device with bare hands and feet.
Time frame: At baseline
Fat-free mass (kg)
Fat-free mass (FFM) will be measured in kilograms using the TANITA® MC-180MA Bioelectric Impedance Analyser in both patients with RRMS and healthy controls. Bioelectrical impedance analysis will be performed 2 hours after a meal, following 5 minutes of rest, with participants standing still on the device with bare hands and feet.
Time frame: At baseline
Total body water (kg)
Total body water (TBW) will be measured in kilograms using the TANITA® MC-180MA Bioelectric Impedance Analyser in both patients with RRMS and healthy controls. Bioelectrical impedance analysis will be performed 2 hours after a meal, following 5 minutes of rest, with participants standing still on the device with bare hands and feet.
Time frame: At baseline
Predicted muscle mass (kg)
Predicted muscle mass (PMM) will be measured in kilograms using the TANITA® MC-180MA Bioelectric Impedance Analyser in both patients with RRMS and healthy controls. Bioelectrical impedance analysis will be performed 2 hours after a meal, following 5 minutes of rest, with participants standing still on the device with bare hands and feet.
Time frame: At baseline
Beck Depression Inventory score
Depressive symptoms will be assessed using the Beck Depression Inventory (BDI), which ranges from 0 to 63. Higher scores indicate more severe depressive symptoms. Commonly used score ranges are 0-9 for minimal depression, 10-16 for mild depression, 17-29 for moderate depression, and 30-63 for severe depression.
Time frame: At baseline
Trait anger score
Anger disposition will be assessed using the Trait Anger subscale of the State-Trait Anger Scale (STAS). Scores range from 10 to 40, with higher scores indicating greater trait anger.
Time frame: At baseline
Anger-in score
Suppressed anger will be assessed using the Anger In subscale of the State-Trait Anger Scale (STAS). Scores range from 8 to 32, with higher scores indicating a greater tendency to suppress anger.
Time frame: At baseline
Anger-out score
Outward expression of anger will be assessed using the Anger Out subscale of the State-Trait Anger Scale (STAS). Scores range from 8 to 32, with higher scores indicating a greater tendency to express anger outwardly.
Time frame: At baseline
Anger control score
Anger control will be assessed using the Anger Control subscale of the State-Trait Anger Scale (STAS). Scores range from 8 to 32, with higher scores indicating better anger control.
Time frame: At baseline
Urinary incontinence symptom-based subtype classification
Urinary incontinence symptoms will be assessed using semi-structured symptom-based urinary incontinence screening questionnaires designed to identify stress, urge, and overflow incontinence patterns. The questionnaires include symptom-oriented items with response options such as yes, no, and "more than half of the time," and additional questions on urinary frequency, nocturia, leakage frequency, and leakage amount where applicable. Participants will be classified according to the predominant symptom pattern identified from the questionnaire responses as stress, urge, or overflow urinary incontinence.
Time frame: At baseline
Correlation between EDSS score and MNA-SF
The correlation between disability severity, as measured by EDSS, and nutritional status as measured by MNA-SF will be evaluated in patients with RRMS.
Time frame: At baseline
Plan to share: Undecided
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Multiple Sclerosis, Relapsing-Remitting→
Antalya Training and Research Hospital